Editorial
|
|
|
|
|
Mirabegron is a case in point
|
|
|
|
New Products
|
|
|
|
|
Still no satisfactory weight loss drugs
|
|
|
|
|
|
|
|
|
|
Poorly effective in urge urinary incontinence
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No place for a patch containing a third-generation progestin
|
|
|
|
|
|
|
|
|
|
|
|
In medullary thyroid cancer: more harmful than beneficial, as is vandetanib
|
|
|
|
Adverse Effects
|
|
|
|
|
Naproxen and low dose ibuprofen are safer
|
|
|
|
|
|
|
|
|
|
1 ovarian cancer per 1000 women exposed to HRT
|
|
|
|
|
|
|
|
|
|
Malformations due to folic acid depletion
|
|
|
|
|
|
|
|
|
|
Reduced gastrointestinal motility exposes to potentially serious consequences
|
|
|
|
Reviews
|
|
|
|
|
First-line empirical treatment in 2015: amoxicillin + clarithromycin + metronidazole
|
|
|
|
|
|
|
|
|
|
|
|
Trials including about 2000 infants showed no measurable impact
|
|
|
|
Outlook
|
|
|
|
|
Health professionals must remain vigilant
|
|
|
|
|
|